Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol

References

• Cohen D, Adachi JD. The treatment of glucocorticoid-induced osteoporosis. J Steroid Biochem Mol Biol. 2004;88:337–49.
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Task Force on osteoporosis guidelines recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 1996;39:1797-801.
   Google Scholar
• Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, et al. A UK consensus group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med. 1998;244:271–92.
   PubMed Web of Science ®Google Scholar
• Adachi JD, Olszynski WP, Hanley DA, Hodsman AB, Kendler DL, Siminoski KG, et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum. 2000;29:228–52.
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology ad hoc committee on glucocorticoid-induced osteoporosis recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Update. Arthritis Rheum. 2001;44:1496–503.
   PubMed Web of Science ®Google Scholar
• Brown JP, Josse RG. Clinical practice guidelines for the diag-nosis and management of osteoporosis in Canada. Can Med Assoc J. 2002;167:1S–345.
   Google Scholar
• Bone and Tooth Society, National Osteoporosis Society, Royal College of Physicians Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. Royal College of Phy-sicians, London 2002.
   Google Scholar
• Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 2000;85:231–6.
   PubMed Web of Science ®Google Scholar
• Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fuku-naga M, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab. 2005;23: 105–9.
   Google Scholar
• Tanaka Y, Okada Y, Nakamura T. Inter- and intracellular sig-naling in secondary osteoporosis. J Bone Miner Metab. 2003;21:61–6.
   Google Scholar
• Barrett-Connor E, Sins ES, Wehren LE, Miller PD, Abbott TA, Berger ML, Santora AC, Sherwood LM. Osteoporosis and frac-ture risk n female patients of different ethnic groups. J Bone Miner Res. 2005;20:185–94.
   PubMed Web of Science ®Google Scholar
• Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced osteoporosis intervention study group. N Engl J Med. 1998;339:292–9.
   PubMed Web of Science ®Google Scholar
• Reginster JY, Kuntz D, Verdickt W, Wouters M, Guillevin L, Menkes CJ, et al. Prophylactic use of alfacalcidol in corticoste-roid-induced osteoporosis. Osteoporos Int. 1999;9(1):75–81.
   PubMedGoogle Scholar
• Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorti-coids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001;44(1):202–11.
   PubMedGoogle Scholar
• de Nijs RNJ, Jacobs JWG, Lems WF, Laan RFJ, Algra A, Hu-isman AM, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med. 2006;355:675–84.
   Google Scholar
• Dykman TR, Gluck OS, Murphy WA, Hahn TJ, Hahn BH. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum. 1985;28:361–8.
   Google Scholar
• McEvoy CE, Ensrud KE, Bender E, Genant HK, Yu W, Griffith JM, et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary dis-ease. Am J Respir Crit Care Med. 1998;157:704–9.
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatol. 2000;39:1383–9.
   Google Scholar
• Walsh LJ, Wong CA, Obome J, Cooper S, Lewis SA, Pringle M, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax. 2001;56:279–84.
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777–87.
   PubMed Web of Science ®Google Scholar
• McKenzie R, Reynolds JC, O'Fallon A, Dale J, Deloria M, Blackwelder W, Straus S. Decreased bone mineral density during low dose glucocorticoid administration in a randomized, placebo controlled trial. J Rheumatol. 2000;27:2222–6.
   Google Scholar
• Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Kaneda K, Minaguchi H, et al. A placebo-controlled, single-blinded study to determine the appropriate alendronate dosage in post-menopausal Japanese patients with osteoporosis. Endocrine J. 1998;45(2):191–201.
   PubMedGoogle Scholar
• Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, et al. A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporosis Int. 1999;10:183–92.
   PubMed Web of Science ®Google Scholar
• Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H, Yamamoto K, et al. Alendronate reduced vertebral fracture risk in postmenopausal Japanese female patients with osteoporosis: a 3-year follow-up study. J Bone Miner Metab. 2004;22:462–8.
   PubMedGoogle Scholar
• Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, et al. The effects of 2-year treatment with the aminobisphosph-onate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest. 1993;92:2577–86.
   PubMed Web of Science ®Google Scholar
• Ravn P, Thompson DE, Ross PD, Christiansen C. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone. 2003;33:150–8.
   PubMed Web of Science ®Google Scholar